Royal Bank of Canada Sells 801,181 Shares of Bruker Corporation $BRKR

Posted by Stanley Muller on Jun 15th, 2026

Royal Bank of Canada cut its stake in shares of Bruker Corporation (NASDAQ:BRKR – Free Report) by 93.9% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 51,969 shares of the medical research company’s stock after selling 801,181 shares during the period. Royal Bank of Canada’s holdings in Bruker were worth $2,448,000 as of its most recent SEC filing.

Other large investors have also bought and sold shares of the company. Los Angeles Capital Management LLC bought a new position in Bruker during the 4th quarter valued at $26,000. Parallel Advisors LLC grew its stake in Bruker by 121.0% in the 4th quarter. Parallel Advisors LLC now owns 875 shares of the medical research company’s stock valued at $41,000 after purchasing an additional 479 shares during the period. Allworth Financial LP grew its stake in Bruker by 40.6% in the 3rd quarter. Allworth Financial LP now owns 890 shares of the medical research company’s stock valued at $29,000 after purchasing an additional 257 shares during the period. Covestor Ltd grew its stake in Bruker by 304.6% in the 4th quarter. Covestor Ltd now owns 1,416 shares of the medical research company’s stock valued at $67,000 after purchasing an additional 1,066 shares during the period. Finally, Parkside Financial Bank & Trust grew its stake in Bruker by 144.6% in the 4th quarter. Parkside Financial Bank & Trust now owns 1,482 shares of the medical research company’s stock valued at $70,000 after purchasing an additional 876 shares during the period. 79.52% of the stock is currently owned by institutional investors.

Insider Activity at Bruker

In other news, VP Mark Munch sold 2,000 shares of the company’s stock in a transaction on Wednesday, April 15th. The stock was sold at an average price of $39.90, for a total transaction of $79,800.00. Following the transaction, the vice president owned 128,443 shares of the company’s stock, valued at $5,124,875.70. This represents a 1.53% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 27.20% of the stock is owned by corporate insiders.

Bruker Price Performance

Shares of NASDAQ BRKR opened at $54.23 on Monday. Bruker Corporation has a one year low of $28.53 and a one year high of $64.54. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.55 and a quick ratio of 0.72. The business’s fifty day moving average price is $44.62 and its 200-day moving average price is $43.84. The stock has a market capitalization of $8.26 billion, a PE ratio of -225.96, a P/E/G ratio of 1.74 and a beta of 1.30.

Bruker (NASDAQ:BRKR – Get Free Report) last issued its quarterly earnings results on Wednesday, May 6th. The medical research company reported $0.31 EPS for the quarter, beating analysts’ consensus estimates of $0.23 by $0.08. Bruker had a positive return on equity of 11.60% and a negative net margin of 0.65%.The firm had revenue of $823.40 million for the quarter, compared to analysts’ expectations of $795.62 million. During the same quarter in the prior year, the firm earned $0.47 EPS. The business’s revenue for the quarter was up 2.7% compared to the same quarter last year. Bruker has set its FY 2026 guidance at 2.100-2.150 EPS. On average, equities research analysts anticipate that Bruker Corporation will post 2.12 EPS for the current year.

Bruker Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, July 7th. Stockholders of record on Monday, June 22nd will be given a dividend of $0.05 per share. This represents a $0.20 dividend on an annualized basis and a dividend yield of 0.4%. The ex-dividend date of this dividend is Monday, June 22nd. Bruker’s dividend payout ratio is currently -83.33%.

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on BRKR shares. JPMorgan Chase & Co. upped their price objective on Bruker from $55.00 to $65.00 and gave the company an “overweight” rating in a research note on Monday, June 8th. UBS Group upped their price objective on Bruker from $40.00 to $45.00 and gave the company a “neutral” rating in a research note on Thursday, May 7th. Citigroup upped their price objective on Bruker from $40.00 to $44.00 and gave the company a “neutral” rating in a research note on Thursday, May 7th. Guggenheim reduced their price objective on Bruker from $58.00 to $50.00 and set a “buy” rating for the company in a research note on Monday, March 30th. Finally, TD Cowen upped their price objective on Bruker from $43.00 to $45.00 and gave the company a “hold” rating in a research note on Thursday, May 7th. One research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, six have assigned a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat, Bruker currently has an average rating of “Hold” and an average price target of $51.31.

Get Our Latest Stock Report on BRKR

About Bruker

(Free Report)

Bruker Corporation, founded in 1960 by physicist Günther Laukien and headquartered in Billerica, Massachusetts, is a leading developer and manufacturer of high-performance scientific instruments and analytical solutions. The company designs systems that enable molecular and materials research across academic, governmental, and industrial laboratories.

Bruker’s product portfolio encompasses nuclear magnetic resonance (NMR) spectrometers for molecular structure and dynamics studies, mass spectrometry platforms for proteomics and metabolomics, X-ray diffraction and scattering instruments for crystallography and materials characterization, atomic force and scanning probe microscopes for nanoscale surface analysis, as well as preclinical imaging systems such as micro-CT and MRI scanners.

In addition to hardware, Bruker provides software suites, applications support, training services, and long-term maintenance agreements to ensure optimal instrument performance.